廣告
香港股市 將在 2 小時 18 分鐘 開市
  • 恒指

    16,385.87
    +134.03 (+0.82%)
     
  • 國指

    5,803.86
    +54.17 (+0.94%)
     
  • 上證綜指

    3,074.22
    +2.84 (+0.09%)
     
  • 道指

    37,775.38
    +22.07 (+0.06%)
     
  • 標普 500

    5,011.12
    -11.09 (-0.22%)
     
  • 納指

    15,601.50
    -81.87 (-0.52%)
     
  • Vix指數

    18.00
    -0.21 (-1.15%)
     
  • 富時100

    7,877.05
    +29.06 (+0.37%)
     
  • 紐約期油

    82.58
    -0.15 (-0.18%)
     
  • 金價

    2,394.00
    -4.00 (-0.17%)
     
  • 美元

    7.8313
    +0.0001 (+0.00%)
     
  • 人民幣

    0.9237
    -0.0002 (-0.02%)
     
  • 日圓

    0.0504
    -0.0000 (-0.02%)
     
  • 歐元

    8.3322
    -0.0022 (-0.03%)
     
  • Bitcoin

    63,562.79
    +1,853.71 (+3.00%)
     
  • CMC Crypto 200

    1,312.03
    +426.49 (+48.16%)
     

Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China

  • Innovent Biologics Inc (OTC: IVBXF) and Sanofi SA (NASDAQ: SNY) have collaborated to develop and commercialize two Sanofi clinical-stage oncology assets - Phase 3 SAR408701 and Phase 2 SAR444245 combined with sintilimab.

  • In addition to the collaboration and license agreement, Sanofi will invest €300 million in Innovent through the subscription of new common shares.

  • SAR408701 (tusamitamab ravtansine) is an antibody-drug conjugate (ADC) targeting a cell-surface glycoprotein that is highly expressed in non-small cell lung cancer (NSCLC), gastric cancer, and other cancers.

  • SAR408701 is currently in a Phase 3 study for second-line NSCLC and global Phase 2 studies in additional indications, including first-line NSCLC, gastric cancers, and other solid tumors.

  • Innovent will be responsible for developing and exclusively commercializing tusamitamab in multiple oncology-based indications in China.

  • Sanofi will receive up to €80 million in development milestone payments and royalties.

  • SAR444245 is currently under Phase 2 studies for skin cancers, gastrointestinal cancer, NSCLC / mesothelioma, head & neck tumors, and lymphoma.

  • Innovent and Sanofi will jointly explore the development of SAR444245 in China in various cancer types, where Innovent will lead the clinical development.

  • Sanofi remains the sole Marketing Authorization holder for both assets and will be fully responsible for SAR245 commercialization.

  • Innovent will receive up to €60 million in development milestone payments and royalties.

  • Price Action: SNY shares are up 0.78% at $49.22 during the market session on the last check Thursday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.